Today marks the official release of the report, ‘Low Vision, quality of life and independence: A review of the evidence on aids and technologies’ by Macular Disease Foundation Australia produced in collaboration with The George Institute for Global Health.
The George Institute for Global Health and the University of New South Wales (UNSW) today announced their intention to form a strategic collaboration to bolster high-impact medical research and transform lives around the world, a priority of both organisations.
Type 2 diabetes often causes damaging effects to the kidneys, sometimes resulting in the need for dialysis or kidney transplantation. The ongoing CANVAS-R trial is testing whether canagliflozin -- a member of a new class of diabetes treatments known as sodium glucose co-transporter 2 (SGLT2) inhibitors -- can slow kidney function decline and provide other benefits to diabetic patients.
"More and more, I think people are realising that this light-touch but personal-touch support can help people to change behaviours, which is fundamental to a lot of chronic health conditions these days."